PPARalpha deficiency in inflammatory cells suppresses tumor growth. - Wikidata - awgldk - TriplyDB

PPARalpha deficiency in inflammatory cells suppresses tumor growth.

PPARalpha deficiency in inflammatory cells suppresses tumor growth.

http://www.wikidata.org/entity/Q33275971

about

Regulation of inflammation in cancer by eicosanoids EET signaling in cancer Orchestration of angiogenesis by immune cells Endothelial colony forming cells and mesenchymal progenitor cells form blood vessels and increase blood flow in ischemic muscle.Effects of PPARα inhibition in head and neck paraganglioma cells Endogenous epoxygenases are modulators of monocyte/macrophage activity Cytochrome P450-derived eicosanoids: the neglected pathway in cancer.Host myeloid cells are necessary for creating bioengineered human vascular networks in vivo.β-Carotene Attenuates Angiotensin II-Induced Aortic Aneurysm by Alleviating Macrophage Recruitment in Apoe(-/-) Mice.The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism.Thrombospondin-1: multiple paths to inflammation.Peroxisome proliferator-activated receptor-α staining is associated with worse outcome in colorectal liver metastases.Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice Molecular Interactions between NR4A Orphan Nuclear Receptors and NF-κB Are Required for Appropriate Inflammatory Responses and Immune Cell Homeostasis.Epoxyeicosatrienoic acids regulate macrophage polarization and prevent LPS-induced cardiac dysfunction.A Selective Novel Peroxisome Proliferator-Activated Receptor (PPAR)-α Antagonist Induces Apoptosis and Inhibits Proliferation of CLL Cells In Vitro and In Vivo The role of nuclear receptors in regulation of Th17/Treg biology and its implications for diseases.PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition.Anticancer Properties of PPARalpha-Effects on Cellular Metabolism and Inflammation.Macrophages, PPARs, and Cancer.Peroxisome proliferator activated receptor α ligands as anticancer drugs targeting mitochondrial metabolism PPARs Mediate Lipid Signaling in Inflammation and Cancer.Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma Agonists Implications of a peroxisome proliferator-activated receptor alpha (PPARα) ligand clofibrate in breast cancer Epoxyeicosanoids promote organ and tissue regeneration.Multiple Interactions between Peroxisome Proliferators-Activated Receptors and the Ubiquitin-Proteasome System and Implications for Cancer Pathogenesis.Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth.PPARalpha Ligands as Antitumorigenic and Antiangiogenic Agents Interactions of PPAR-alpha and adenosine receptors in hypoxia-induced angiogenesis.PPAR Agonists for the Prevention and Treatment of Lung Cancer.Tumor-associated macrophages as targets for tumor immunotherapy.Regulation of endothelial cell functions by basement membrane- and arachidonic acid-derived products.PPARs: Interference with Warburg' Effect and Clinical Anticancer Trials.Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key?Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy Systems biology: a therapeutic target for tumor therapy.The role of the tumor microenvironment in regulating angiogenesis.Differential effects on lung cancer cell proliferation by agonists of glucocorticoid and PPARα receptors.Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy.

P2860

Q24564308-9A32D56E-EDCD-42CA-AE18-76B3CF59162F Q28250730-864C2219-10CB-4274-A9A2-6CEA0B1196E7 Q28389236-A72C0268-0BAF-4A0A-A170-7F31CAB416CC Q33677801-B6C0479E-B6F8-4B4E-A42A-E5F40520ABEE Q33779008-82BDC251-DC37-4993-AD63-8BF56B8CC6AE Q34058704-81DC238E-A7A1-4656-91F1-5B093DDD2BBC Q34143118-2989DCB0-EE38-459E-A763-7700B397079C Q34163217-2D7E2D5A-820F-48BB-9F4E-D27907720DF1 Q34796427-EF996410-5573-4522-8845-AFAF2626235E Q35092818-1113BD22-9402-4363-8976-C1ED87D4532B Q35098885-BAEAF220-6118-44C3-978A-18811365AC28 Q35180034-B853F0E5-FC22-4D6E-A604-F9F05022F82D Q35640579-5F697314-15D8-41DF-B009-3243A86D6953 Q35679745-DDBD48C1-0A25-4DFF-BF3E-D1678A23146C Q35742804-B7E4ACBF-AAB6-4E6C-ABFC-5B84FB5A2AB9 Q36025695-9B24FA1E-BF60-43FD-9694-12BAC2E5A7C2 Q36085086-676738A5-0F6A-4C28-89F5-6DC97EEF1458 Q36458927-15F7C7B4-64DF-4FA2-AB8A-0674E924D1FE Q36675898-32F83184-5884-4609-B458-F3382FE09760 Q36743885-3FEFDF9D-BD6C-4C7F-AC8C-326892301957 Q36781253-0D2BFB36-2918-4AB6-A648-0F35DDA13F54 Q37021709-806832BD-3822-4E58-9E52-4528098C9126 Q37077098-71597A94-1257-4B48-B1AE-49C6E557286D Q37085828-284432F2-C508-4CD2-BA14-DB860367F172 Q37104034-49CED8DE-784F-4441-92D8-D4319FC2C679 Q37190455-FA0C05C3-8520-4E76-98D7-1C439F7F036F Q37231752-25A8F480-5BA0-4D23-A598-4ED6605F96AE Q37251719-CD430E91-AC03-4817-A82B-28B2A8890141 Q37421898-F12AD7E9-E048-4326-9C54-A01AF6FF7EB9 Q37681630-ACE0FC9A-E40A-4BDF-80FF-5A462A61B09F Q37773280-D562B738-1726-4224-968E-69EF3D5870C8 Q37787958-0D951E8B-6435-4EE9-B575-F42B3720221A Q39609137-89BFDF4C-6BC7-4650-B98F-D555109C198D Q40281693-778CCE20-27C7-4B79-81CC-994E8DEA0BD9 Q41694098-1C7527E5-0C8F-4BD8-BB92-C9F21F9C85DA Q41961938-B3EA7AFD-4CAF-4466-A1FF-98DD08C8B811 Q42703796-D920B84D-F5E6-4EA0-88F2-36970DB774D1 Q43545244-0A0FF578-AF86-4B21-82CE-B968F562CEB0 Q55012882-4211ECAE-2479-4ECA-A0BB-141B184D31F6

P2860

PPARalpha deficiency in inflammatory cells suppresses tumor growth.

http://www.wikidata.org/entity/Q33275971

description

2007 nî lūn-bûn

@nan

2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

PPARalpha deficiency in inflammatory cells suppresses tumor growth.

@ast

PPARalpha deficiency in inflammatory cells suppresses tumor growth.

@en

PPARalpha deficiency in inflammatory cells suppresses tumor growth.

@nl

type

label

PPARalpha deficiency in inflammatory cells suppresses tumor growth.

@ast

PPARalpha deficiency in inflammatory cells suppresses tumor growth.

@en

PPARalpha deficiency in inflammatory cells suppresses tumor growth.

@nl

prefLabel

PPARalpha deficiency in inflammatory cells suppresses tumor growth.

@ast

PPARalpha deficiency in inflammatory cells suppresses tumor growth.

@en

PPARalpha deficiency in inflammatory cells suppresses tumor growth.

@nl

P1433

Q33275971-E54775BE-0390-4D1E-8484-75D45C762799

P1476

Q33275971-8AA7A8F8-2BB2-4957-8574-72FCF21F7CDE

P2093

Q33275971-12B3F565-954C-4687-8A87-3B91FFA4C406

Q33275971-84B79F07-8006-4E42-B1E9-9DA098559BF1

Q33275971-9530EB25-46FB-47D4-ACD1-83549AF8C586

Q33275971-ADF1A799-733C-44BD-8D2C-D917C49370AF

Q33275971-AEA506EF-9146-4D1A-ABD5-B4180894F6F2

Q33275971-B46B060F-844E-4992-A4C6-06A2F0884AE1

Q33275971-F3992E9C-FF7E-4606-816B-E7C3AC42AEEF

P2860

Q33275971-02960235-5AEB-481D-8249-9A03B0247B43

Q33275971-0C1FDF49-004A-420C-B8B8-D798AC82F19D

Q33275971-1D98AC6D-2096-4CB7-93D7-DECCFF092DD2

Q33275971-1ECEA42F-EB85-4359-BC1B-4E4DA0CCF136

Q33275971-22F8E1FE-9E6C-4331-8199-8BC657B207F8

Q33275971-29B5312C-9613-418E-A688-9FFAFB8DC3DD

Q33275971-2FC1EE04-E50D-465D-BD98-230832CF4267

Q33275971-31D12466-AD00-43A0-8D0D-853243A9F81D

Q33275971-40BF5530-3BBF-464D-900E-DE2BAB6EEA4B

Q33275971-42D52F52-3BD5-40AF-94E0-CAFC142155B0

P304

Q33275971-8D2946E4-F52F-4B70-BB88-280F27FB7E00

P31

Q33275971-9F000E9E-6247-480C-8734-8CA633153C29

P356

Q33275971-D6770AA8-56F7-4964-9F3B-7313BE3B9A6A

P407

Q33275971-2552D1FD-E497-4C7D-A08F-5D3510CADC4A

P433

Q33275971-935210CF-C731-4ABE-A21B-93961AABE4B0

P478

Q33275971-3F419A2A-E196-46DF-98FA-904A70459746

P50

Q33275971-A6EE8ED1-DFB0-4AEC-A6C2-5FF0F053CFCD

Q33275971-F963E8CF-4254-4D92-85CA-41019396D48A

P577

Q33275971-C550C42A-E8A8-4036-BA9A-EF6CD3EE8CC6

P5875

Q33275971-6DCB740F-CE0A-42CC-8F0F-1A0FC3C1E1FB

P698

Q33275971-E5FC7E12-C773-4CF8-8DF4-C9DD9F9B1242

P921

Q33275971-E2DEA71C-FDB8-4460-867A-F989D64209E4

P932

Q33275971-5D306707-175B-40CE-A971-16CE6FA975A2

P356

JOURNAL.PONE.0000260

P1433

P1476

PPARalpha deficiency in inflammatory cells suppresses tumor growth.

@en

P2093

Arja Kaipainen

http://www.w3.org/2001/XMLSchema#string

Catherine Butterfield

http://www.w3.org/2001/XMLSchema#string

Diane Bielenberg

http://www.w3.org/2001/XMLSchema#string

Dipak Panigrahy

http://www.w3.org/2001/XMLSchema#string

Judah Folkman

http://www.w3.org/2001/XMLSchema#string

Richard Mulligan

http://www.w3.org/2001/XMLSchema#string

Sui Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

Inflammation and cancer

Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators

Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice

Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts

The mechanisms of action of PPARs

PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice

Paradoxical roles of the immune system during cancer development

P304

e260

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0000260

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Gustavo Mostoslavsky

P577

2007-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6478474

http://www.w3.org/2001/XMLSchema#string

P698

17327920

http://www.w3.org/2001/XMLSchema#string

P921

P932

1800345

http://www.w3.org/2001/XMLSchema#string